Precision Medicine advocate and Personalized Healthcare early adopter | +15y of Commercial and Market Development Leadership experience | Medical Device, Companion Diagnostics (CDx) and IVD expert
Survival outcomes on CDK4/6 inhibitors from two trials - based on intrinsic subtypes https://lnkd.in/dsH5fT2e 2nd generation Genexpression tests can generate clinical insights.
Professor of Experimental Pathology at Amsterdam UMC, Cancer Center Amsterdam, location VUmc
Happy to share our review by Stèfanie Dick on the clinical indications of #methylationmarkers for the early detection and clinical managment of cervical HSIL and #cervicalcancer. #HPV #DNAmethylation
Physician | Founder, Women in Medicine® & Women in Medicine Summit™ | Tenured Assoc Prof | GI Oncologist |Director Communication Strategies & Digital Innovation, UI Health | Healthcare Thought Leader | Keynote Speaker
📢 Incorporating ctDNA and Novel Therapies into Colorectal Cancer Practice 📢 The landscape of colorectal cancer (CRC) treatment is rapidly evolving, with groundbreaking advancements reshaping how we approach this complex disease. Among the most promising innovations are the integration of circulating tumor DNA (ctDNA) analysis and novel therapeutic strategies. Here's how these developments are transforming colorectal cancer care: 🔬 Circulating Tumor DNA (ctDNA): This minimally invasive biomarker allows for real-time monitoring of tumor dynamics. By detecting genetic mutations and alterations shed by tumors into the bloodstream, ctDNA provides valuable insights into disease progression, treatment response, and potential relapse. This personalized approach enables more precise and timely adjustments to therapy, enhancing patient outcomes. 💊 Novel Therapies: The introduction of targeted therapies and immunotherapies has revolutionized CRC treatment. Drugs targeting specific genetic mutations, such as BRAF or KRAS, and immune checkpoint inhibitors, are offering new hope for patients with advanced or refractory CRC. These therapies are designed to attack cancer cells while sparing healthy tissue, leading to improved efficacy and reduced side effects. 👩⚕️ Clinical Integration: Incorporating these advancements into clinical practice requires a multidisciplinary approach. Oncologists, pathologists, and genetic counselors must collaborate to interpret ctDNA results and tailor treatment plans. Education and training on the latest therapies and biomarker technologies are crucial for healthcare providers to stay at the forefront of CRC care. 🔍 Research and Trials: Ongoing clinical trials are essential for validating the effectiveness of ctDNA-guided treatment and novel therapies. Participation in these trials not only advances scientific knowledge but also provides patients access to cutting-edge treatments that may improve survival and quality of life. 🌟 Patient-Centered Care: At the heart of these innovations is the commitment to patient-centered care. By leveraging ctDNA analysis and novel therapies, we can offer more personalized, effective, and compassionate treatment options, ensuring that every patient receives the best possible care tailored to their unique needs. The future of colorectal cancer treatment is promising, with ctDNA and novel therapies paving the way for more precise, effective, and personalized care. Together, we can continue to push the boundaries of what's possible in the treatment of patients with CRC. #ColorectalCancer #ctDNA #NovelTherapies #CancerCare #OncologyInnovation #PatientCare #MedicalAdvancements https://lnkd.in/ebJcecqR
Asset assessment for in licensing/out licensing, AI, R&D, US FDA IND Regulatory Submission for BTD/ODD/AA, Global/local Clinical Studies, Board of Directors, International Speaker, CDP, M&A, Hiring, CME advice, Editor.
By dissecting molecular pathways associated with treatment resistance, we sought to define patient #sub-groups and actionable #targets for next-line treatment. Great to consider
Immunologist with expertise in Flow Cytometry Assay development and validation for global clinical trials including for Cell and Gene Therapy
It will be a great webinar on CAR T cells.
In the ever-evolving landscape of CAR T cell therapies, what are the best practices for overcoming challenges related to (1) monitoring CAR T cells, (2) ensuring patient safety, and (3) assessing the therapy response? Our experts Goran Marinković, Ph.D. Karthikeyan Devaraju, nele langenaken and Nithianandan Selliah, Ph.D will dive deeper into this questions and guide you along the way! Register here: https://lnkd.in/eGrhq-2b
Please join us on Monday, 15 - April, for webinar on how CAR T assay data can be utilized to monitor CAR T cells, patient response to treatment and patient safety
In the ever-evolving landscape of CAR T cell therapies, what are the best practices for overcoming challenges related to (1) monitoring CAR T cells, (2) ensuring patient safety, and (3) assessing the therapy response? Our experts Goran Marinković, Ph.D. Karthikeyan Devaraju, nele langenaken and Nithianandan Selliah, Ph.D will dive deeper into this questions and guide you along the way! Register here: https://lnkd.in/eGrhq-2b
In this Healio Video Perspective from the #ARVO2024 meeting, Allen C. Ho, MD, FASRS, discusses 12-month data on MCO-010 optogenetic therapy for patients with retinitis pigmentosa. https://lnkd.in/gkXwrqHx
Researchers will analyze the ability of HER2DX scores to predict patient outcomes in the Phase II CompassHER2 pCR trial.
TOMORROW - Join us for #WebinarWednesday with the ORS Preclinical Models Section to explore how multiple omics techs combine for deeper insight into disease mechanisms & therapeutic responses in #musculoskeletal research. Register now: https://bit.ly/4dLKzFM
New in JBC press: "Scientists' findings suggest that the CREPT-MYC interaction is crucial for the progression of MYC-driven cancers and presents a potential target for therapeutic intervention." Learn more: https://lnkd.in/eKHkTrRd
Strategic Legal Executive | Intellectual Property and Commercial Transactions | Expert in Patents, Licensing, Privacy, AI, and Corporate Governance | Entrepreneur | Board Advisor
Timely update on the status of #CRISPR Clinical Trials. In late 2023, we saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This update tracks the progress CRISPR clinical trials since they first began, and this milestone has been anticipated for some time, but its speed is still noteworthy. #medicine #medicaltechnology #clinicaltrials https://lnkd.in/gaGv7PPN
